Management ChangeJul 10, 2026, 04:40 PM
LB Pharmaceuticals Grants Equity Award to New SVP, Clinical Operations
AI Summary
LB Pharmaceuticals Inc. announced an equity award grant to Christopher Zergebel, its new Senior Vice President, Clinical Operations. The award, an inducement grant under Nasdaq rules, consists of an option to purchase 75,000 shares of common stock at an exercise price of $32.95 per share. The option vests over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter, subject to continuous service. The company is a late-stage biopharmaceutical company developing LB-102 for neuropsychiatric disorders.
Key Highlights
- LB Pharmaceuticals granted an equity award to Christopher Zergebel, new SVP, Clinical Operations.
- The award is an inducement grant under Nasdaq Listing Rule 5635(c)(4).
- Mr. Zergebel received an option to purchase 75,000 shares of common stock.
- The exercise price is $32.95 per share, the closing price on the grant date.
- The option vests over 4 years, with 25% on the first anniversary and 1/48th monthly thereafter.
Price Impact
More from LBRX